Charles Lacey

Dept of Infectious Diseases, Hull York Medical School, University of York, United Kingdom

Dr Lacey is Honorary Reader in Sexual Health and HIV Medicine at The Hull York Medical School, University of York, UK. He undertook his undergraduate training at Guy's Hospital Medical School, London, and then postgraduate training in Cambridge and Bristol, UK. He was Consultant Physician in Genitourinary Medicine at the General Infirmary, Leeds, where he developed his interests in sexually transmitted disease research. He has served as a consultant to HPV and HSV vaccine development programmes for GlaxoSmithKline, Merck and Roche.

From 1996 to 2004 he was Senior Lecturer, Imperial College London, and Consultant Physician, St Mary's Hospital. There he directed studies of the development of vaginal microbicides for the prevention of HIV transmission. Current studies are also exploring the potential of mucosal vaccination against HIV. Dr Lacey holds programme grant funding from the European Commission, the National Institutes of Health, USA, and the Bill and Melinda Gates Foundation. He co-ordinates trials in York and Africa and, with a large group of African and UK colleagues, is conducting a major multicentre phase III vaginal microbicide trial in six centres in Africa.

Any competing interests declared are displayed with individual evaluations.

: Infectious Diseases > Sexually Transmitted Diseases (without HIV) (11 November 2005 - 31 January 2007)

All recent recommendations

• 3.0
  Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.
  Recommended by Charles Lacey
  
• 6.0
  Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
  Recommended by Charles Lacey
  
• 6.4
  Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
  Recommended by Charles Lacey, Asok Antony
  
• 3.0
  Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study.
  Recommended by Charles Lacey